AUTHORS
Sun-Hye Ko, MD, PhD, Tomohiro Aoki, MD, PhD2, Tameem Almahmoud, MD3, Wafaa Aljizani Jr, MD4, Chathuri Abeyakoon, MD5, Abi Vijenthira, MD, MS6, Chloe Yang, MD7, Michael Crump, MD8, Robert Kridel, MD9, Sita Bhella, MD10, Vishal Kukreti, MD11, Ali Sakhdari, MD, MSc12, Anca Prica13, John Kuruvilla, MD14, Angela Punnett, MD15
AFFILIATIONS
1 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
2 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
3 The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
4 The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
5 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
6 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
7 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
8 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
9 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
10 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
11 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
12 Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
13 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
14 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
15 The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
ABSTRACT
Introduction
Systemic ALCL differs by age in presentation and treatment, and pediatric and adult patients are evaluated using different staging systems. Although pediatric ALCL is generally considered to have a better prognosis, direct age-based comparisons and cross-age comparability of age-specific staging systems remain uncertain.
Methods
We retrospectively studied 79 patients with systemic ALCL treated at Princess Margaret Cancer Centre and The Hospital for Sick Children from 2010 to 2024 (29 pediatric, 50 adult). Clinical characteristics, treatment patterns, progression-free survival (PFS), and overall survival (OS) were compared by age using Kaplan–Meier methods, 5-year restricted mean survival time (RMST), and minimally adjusted Cox models. Adults were staged by Ann Arbor and restaged by Murphy/St. Jude criteria; pediatric patients were staged by Murphy/St. Jude and restaged by Ann Arbor. A prespecified 6-month landmark analysis assessed early progression and subsequent OS. Among patients with first progression, post-progression PFS was measured from first progression to second progression or death, and post-progression OS from first progression to death.
Results
Pediatric patients more often had ALK-positive disease (93% vs 52%; p<0.001), B symptoms (76% vs 34%; p<0.001), and mediastinal involvement (48% vs 14%; p=0.001), whereas ECOG performance status ≥2 occurred only in adults (0% vs 19%; p=0.022). First-line therapy differed: pediatric patients mainly received ALCL-99 (79%) or ANHL0131 (10%), whereas adults received CHOP/CHOEP (72%) or brentuximab vedotin (BV)-containing regimens (18%). Across all lines, BV exposure was higher in adults (42% vs 14%; p=0.012), whereas crizotinib was confined to pediatric patients (17% vs 0%; p=0.005). Stem cell transplantation (SCT) rates were comparable (24% vs 18%; p=0.568), but approaches differed: pediatric recipients predominantly underwent allogeneic SCT (6/7 [86%], usually 3rd/4th line), whereas all adult recipients initially underwent autologous SCT (9/9 [100%], most commonly 2nd line), with 1 later receiving allogeneic SCT.
With median follow-up of 63 months (IQR, 29–95), 5-year PFS was 63.1% in pediatric patients and 60.9% in adults (p=0.812), and 5-year OS was 85.3% and 74.8% (p=0.330). In the ALK-positive subgroup, 5-year PFS and OS also did not differ by age (63.9% vs 62.9%, p=0.943; 88.1% vs 79.2%, p=0.440). Five-year RMST and minimally adjusted Cox models likewise showed no significant age-group effect.
Reciprocal Ann Arbor and Murphy staging showed limited concordance (exact agreement: 44.0% in adults, 48.3% in children; weighted κ=0.666 and 0.377, respectively). Discordance was directional: 19 of 24 Ann Arbor stage IV adults (79.2%) were reclassified to Murphy stage III, while 6 of 17 Murphy stage III children (35.3%) were reclassified as Ann Arbor stage IV. Murphy staging strongly stratified outcomes (global log-rank p=0.009 for PFS and p=0.001 for OS), and Murphy stage IV remained associated with inferior PFS (HR, 5.42; p=0.011) and OS (HR, 18.76; p=0.014) in minimally adjusted models in pediatric ALCL. By contrast, Ann Arbor stage did not stratify adult PFS or OS, whereas older age was associated with inferior OS in adults (HR per 10-year increase, 1.46; p=0.045). Neither reciprocal Murphy staging in adults (PFS p=0.524; OS p=0.088) nor reciprocal Ann Arbor staging in pediatrics (PFS p=0.699; OS p=0.431) significantly stratified survival outcomes.
Among 73 landmark-eligible patients, 5-year post-landmark OS was 91.4% without progression by 6 months versus 33.3% with early progression (p<0.001). In a separate analysis of 29 patients with first progression, progression within 6 months was associated with lower 5-year post-progression PFS (0% vs 61.9%; HR, 11.57; 95% CI, 3.53–37.95; p<0.001) and OS (26.7% vs 69.2%; HR, 4.25; 95% CI, 1.34–13.49; p=0.014) than progression after 6 months.
Conclusion
Pediatric and adult systemic ALCL showed distinct clinical phenotypes and treatment pathways, but survival did not differ significantly between age groups. Ann Arbor and Murphy stage categories were not directly interchangeable across age groups. Murphy staging identified high-risk pediatric disease, whereas progression within 6 months consistently identified patients with inferior subsequent and post-progression outcomes. These findings caution against cross-age interpretation of nominal stage categories and support dynamic response assessment for risk refinement.
DISCLOSURES
Sun-Hye Ko, MD, PhD: No relevant conflicts of interest to declare.